Mashal Robert 4

What Happened
Robert Mashal, a director of Nuvation Bio (NUVB), was granted an award of 123,397 derivative shares (reported as an acquisition, code A) on May 21, 2026. The grant is recorded with an acquisition price of $0.00 (derivative instrument), so no immediate cash value is reported in the Form 4. This is a compensation award (an option/derivative grant), not an open-market purchase or sale.

Key Details

• Transaction date: May 21, 2026; Form 4 filed May 26, 2026 (filed late — see below).
• Instrument/price: Derivative award (option) of 123,397 shares, $0.00 acquisition price.
• Shares owned after transaction: Not reported in the provided filing.
• Footnote (vesting): 100% of the shares subject to the option vest on the earlier of (i) the one‑year anniversary of the grant date or (ii) the next shareholder annual meeting, subject to Mashal’s continuous service through the applicable vesting date.
• Timeliness: The Form 4 was filed May 26, 2026 for a May 21, 2026 grant — later than the typical two-business-day filing window, and is marked late.

Context
This was a compensation award (derivative option grant). Such grants are common for directors and are intended to align interests with shareholders; they do not by themselves indicate a personal purchase or sale of stock. The award vests subject to continued service, so the recipient does not have immediate, unrestricted shares unless and until vesting requirements are met. The late filing is a reporting issue rather than a trading signal, but it may be noted by investors and regulators.